Source:http://linkedlifedata.com/resource/pubmed/id/16640812
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2006-4-27
|
| pubmed:abstractText |
Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of non-Hodgkin's lymphomas. With few exceptions (eg, anaplastic large-cell lymphoma expressing the anaplastic lymphoma kinase), PTCLs have generally been reported to have a worse prognosis compared with B-cell lymphomas. Despite the poor outcome after conventional therapy, the impact of high-dose therapy with autologous or allogeneic stem cell transplantation (SCT) in these rare diseases is poorly defined mainly because of the lack of prospective PTCL-restricted studies. Most data exist for high-dose therapy with autologous SCT in relapsing or refractory disease. Because most studies showed similar results for PTCL compared with aggressive B-cell lymphomas in which high-dose therapy with autologous SCT is accepted as standard therapy, this approach seems appropriate in relapsing or refractory PTCL. Results for high-dose therapy with autologous SCT as first-line therapy mainly rely on studies on aggressive lymphomas that also included lymphomas of the T-cell phenotype. Our own recently published PTCL-restricted prospective study confirmed the feasibility with only moderate toxicity and a good response rate. Overall, patients with a good remission status after induction therapy exhibited a high complete response rate after transplantation, and at least a subgroup of patients remained in long-term remission. The greatest uncertainty exists for the impact of allogeneic SCT after high-dose therapy. In refractory or relapsing PTCL, this approach might improve the outcome for eligible patients, especially when using reduced-intensity conditioning. Overall, because data on high-dose therapy for PTCL are limited, larger and randomized studies are necessary to definitely confirm the preliminary results.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1557-9190
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
373-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16640812-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16640812-Combined Modality Therapy,
pubmed-meshheading:16640812-Dose-Response Relationship, Drug,
pubmed-meshheading:16640812-Drug Administration Schedule,
pubmed-meshheading:16640812-Female,
pubmed-meshheading:16640812-Graft Rejection,
pubmed-meshheading:16640812-Graft Survival,
pubmed-meshheading:16640812-Humans,
pubmed-meshheading:16640812-Lymphoma, T-Cell, Peripheral,
pubmed-meshheading:16640812-Male,
pubmed-meshheading:16640812-Maximum Tolerated Dose,
pubmed-meshheading:16640812-Prognosis,
pubmed-meshheading:16640812-Randomized Controlled Trials as Topic,
pubmed-meshheading:16640812-Risk Assessment,
pubmed-meshheading:16640812-Severity of Illness Index,
pubmed-meshheading:16640812-Stem Cell Transplantation,
pubmed-meshheading:16640812-Survival Analysis,
pubmed-meshheading:16640812-Transplantation, Homologous,
pubmed-meshheading:16640812-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
The role of high-dose therapy in peripheral T-cell lymphomas.
|
| pubmed:affiliation |
Medizinische Poliklinik, University of Wuerzburg, Germany. p.reimer@medizin.uni-wuerzburg.de
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Review
|